Treating HER2+ breast cancer with brain metastases

Erika Hamilton, MD, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, talks on the current treatment landscape for patients with HER2+ breast cancer with brain metastases, highlighting use of the tyrosine kinase inhibitors lapatinib, neratinib and tucatinib, as well as giving an overview of the challenges of treating brain metastases. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.